|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007102,
umls-concept:C0056154,
umls-concept:C0086418,
umls-concept:C0205195,
umls-concept:C0334227,
umls-concept:C0385242,
umls-concept:C0441655,
umls-concept:C1326205,
umls-concept:C1336646,
umls-concept:C1515655,
umls-concept:C1533691,
umls-concept:C1705952,
umls-concept:C2349975
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-2-2
|
|
pubmed:abstractText |
The present study indicated that the combination of TRAIL/Apo-2L and CA-4 exerted synergistic anti-proliferative effect against human colon carcinoma cells including SW-620 and HCT-116 in vitro. Moreover, the increased anti-tumor efficacy of TRAIL/Apo-2L combined with CA-4 was further validated on SW-620 xenograft model in nude mice. These enhanced anti-cancer activities were accompanied by caspase-mediated apoptosis. Furthermore, it was identified that NF-?B as the major determinant of TRAIL/Apo-2L resistance could be blocked in cytoplasm by TRAIL/Apo-2L plus CA-4 treatment. Taken together, these findings build the rationale for further (pre)clinical development of TRAIL/Apo-2L and CA-4 against colorectal cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1872-7980
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
302
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
11-9
|
|
pubmed:meshHeading |
pubmed-meshheading:21236562-Animals,
pubmed-meshheading:21236562-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21236562-Apoptosis,
pubmed-meshheading:21236562-Caspases,
pubmed-meshheading:21236562-Cell Line, Tumor,
pubmed-meshheading:21236562-Cell Survival,
pubmed-meshheading:21236562-Colonic Neoplasms,
pubmed-meshheading:21236562-Dose-Response Relationship, Drug,
pubmed-meshheading:21236562-Drug Synergism,
pubmed-meshheading:21236562-HCT116 Cells,
pubmed-meshheading:21236562-Humans,
pubmed-meshheading:21236562-Immunoblotting,
pubmed-meshheading:21236562-Mice,
pubmed-meshheading:21236562-Mice, Nude,
pubmed-meshheading:21236562-NF-kappa B,
pubmed-meshheading:21236562-Poly(ADP-ribose) Polymerases,
pubmed-meshheading:21236562-Protein Transport,
pubmed-meshheading:21236562-Stilbenes,
pubmed-meshheading:21236562-TNF-Related Apoptosis-Inducing Ligand,
pubmed-meshheading:21236562-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Enhanced anti-tumor activity by the combination of TRAIL/Apo-2L and combretastatin A-4 against human colon cancer cells via induction of apoptosis in vitro and in vivo.
|
|
pubmed:affiliation |
Institute of Pharmacology and Toxicology, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
